title: A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV.
abstract: OBJECTIVE
  The aim was to compare the efficacy of intravitreal therapy with bevacizumab and ranibizumab for choroidal neovascularization (CNV) in pathologic myopia (PM).
  
  
  METHODS
  This was a prospective multicenter randomized nonblinded trial.
  
  
  RESULTS
  In seven centers, 78 eyes were randomized 1:1 to treatment with bevacizumab (group B, 40 eyes) or ranibizumab (group R, 38 eyes) given with an "on demand" regimen (PRN). The mean follow-up was 19 months (SD 2, range 12-24). The mean BCVA at baseline was 0.60 logMAR (20/80 Snellen equivalent, Seq) and 50 letter score (ls). Mean final BCVA was 0.51 LogMAR (20/63 Seq) and 57 ls (p = 0.0009 and p = 0.0002, respectively). In group B, mean basal BCVA was 0.52 logMAR (20/63 Seq) and 54 ls, and final BCVA was 0.51 logMar (20/63 Seq) and 57 ls. In group R, mean basal BCVA was 0.62 logMAR (20/80 Seq) and 45 ls, and the final values were 0.50 logMAR (20/63 Seq) and 58 ls. Statistical comparison of the two groups showed no significant difference (logMAR p = 0.90 and letters p = 0.78). Multivariate analysis showed no influence of age or previous photodynamic treatment (PDT) on final visual changes. The mean number of treatments in the first year was 2.7 in group B and 2.3 in group R (p = 0.09).
  
  
  CONCLUSIONS
  Myopic CNV equally benefits from on-demand intravitreal injection of either bevacizumab or ranibizumab; the therapeutic effect is independent of previous PDT and age.
authors.affiliation: Unità operativa di Oftalmologia, Ospedale di Melegnano, via Pandina, Melegnano, (MI), Italy. pece.retina@mclink.it.
authors.forename: Alfredo
authors.initials: A
authors.lastname: Pece
authors.affiliation: Fondazione Retina 3000, Milano, Italia.
authors.forename: Paolo
authors.initials: P
authors.lastname: Milani
authors.affiliation: Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche, Sezione di Oftalmologia, Università di Palermo, Palermo, Italia.
authors.forename: Carla
authors.initials: C
authors.lastname: Monteleone
authors.affiliation: Dipartimento di Specialità Chirurgiche, Sezione di Oftalmologia, Università di Messina, Messina, Italia.
authors.forename: Costantino John
authors.initials: CJ
authors.lastname: Trombetta
authors.affiliation: Dipartimento di Scienze Oftalmologiche, Università di Napoli, Naples, Italia.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: De Crecchio
authors.affiliation: Retina Center, Rome, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Fasolino
authors.affiliation: Dipartimento di Scienze per la Promozione della Salute e Materno Infantile, Università di Palermo, Palermo, Italia.
authors.forename: Domenica
authors.initials: D
authors.lastname: Matranga
authors.affiliation: Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche, Sezione di Oftalmologia, Università di Palermo, Palermo, Italia.
authors.forename: Salvatore
authors.initials: S
authors.lastname: Cillino
authors.affiliation: Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche, Sezione di Oftalmologia, Università di Palermo, Palermo, Italia.
authors.forename: Maria
authors.initials: M
authors.lastname: Vadalà
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000188:drug therapy* / Q000503:physiopathology; D011446:Prospective Studies; D000069579:Ranibizumab / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab
keywords: Bevacizumab; CNV; Pathological myopia; Ranibizumab